Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

(STAT News) How a dinner in Paris revived talks for Sanofi’s $9.5 billion deal for Blueprint Medicines. For Blueprint Medicines, a monumental meal in the City of Bridges helped bring back to life ...

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

A high-level overview of Blueprint Medicines Corporation (BPMC) stock. View (BPMC) real-time stock price, chart, news, analysis, analyst reviews and more.

Apple’s efforts to expand its manufacturing footprint in India have hit a roadblock. Foxconn, the tech giant’s key assembly partner, has quietly recalled a la ...

Sanofi has entered into an agreement to acquire Blueprint Medicines for $129 per share, or about $9.1 billion. Additional contingent value rights bring the total potential deal value to $9.5 billion.

Learn about the executive team and board of directors at Blueprint Medicines Corp (BPMC:XNAS) and review their bios and compensation over the latest fiscal years.

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...

Find the latest Blueprint Medicines Corporation (BPMC) stock quote, history, news and other vital information to help you with your stock trading and investing.